ARTICLE | Top Story
Positive Phase III results for Tracleer
May 2, 2001 7:00 AM UTC
Actelion (SWX:ATLN) and partner Genentech (DNA) reported that in its BREATHE-1 U.S. Phase III study of the oral endothelin antagonist Tracleer bosentan, patients with pulmonary arterial hypertension (...